Gohibic is a medicine used to treat acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2 (the virus that causes COVID-19). ARDS is a condition in which swelling in the lungs causes inflammation and fluid to build up in the air sacs, causing severe difficulty breathing. Gohibic is used in adults who are being treated with corticosteroid (medicines to reduce inflammation) and mechanical ventilation (breathing assisted by a machine) with or without extracorporeal membrane oxygenation (ECMO, life support that can help a person whose lungs and heart aren't working properly). Gohibic contains the active substance vilobelimab.
Therapeutic Indication
### Therapeutic indication Gohibic is indicated for the treatment of adult patients with SARS-CoV2-induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids as part of Standard of Care and receiving invasive mechanical ventilation (IMV) (with or without extracorporeal membrane oxygenation (ECMO)).
Therapeutic Area (MeSH)
ATC Code
L04AJ10
ATC Item
xl 04 aj 10
Pharmacotherapeutic Group
Immunosuppressants, Complement inhibitors
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| vilobelimab | N/A | Vilobelimab |
EMA Name
Gohibic
Medicine Name
Gohibic
Aliases
N/ANo risk management plan link.
